You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: infliximab increases response and remission rates in fistulising or treatment-resistant Crohn’s disease

https://doi.org/10.1136/ebm.7.6.186

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    ; Marshall JK, Blackhouse G, Goeree R, et al.Infliximab for the treatment of Crohn’s disease: a systematic review and cost-utility analysis. Technology report no. 24. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002. http://www.ccohta.ca..

    
 
 QUESTION: In patients with fistulising or treatment-resistant Crohn’s disease, is infliximab safe and effective?

    Data sources

    Studies were identified by searching Medline, EMBASE/Excerpta Medica, Current Contents, CINAHL, HealthSTAR, TOXLINE, the Cochrane Library, Drug Info Full Text, Pharmaceutical & Health Care Industry News, PharmaProjects, and Pharmaceutical News Index (1990 to May 2001). Scientific meeting abstracts were searched; major clinical gastroenterology journals were hand searched (to August 2001); and authors, government agencies, and pharmaceutical companies were contacted.

    Study selection

    2 reviewers independently selected English-language randomised controlled trials (RCTs) that reported clinical end points for infliximab treatment in adults with fistulising or treatment-resistant Crohn’s disease.

    Data extraction

    2 independent reviewers extracted data on study centres, source of funding, …

    View Full Text

    Footnotes

    • Source of funding: not stated.

    • For correspondence: Dr J K Marshall, McMaster University, Hamilton, ON, Canada. Email marshallj{at}mcmaster.ca.